This article reviews the World Health Organization (WHO) priority pathogens list relevant to neonatal sepsis and proposes a WHO multiexpert stakeholder meeting to promote the development of a neonatal priority antibiotic development list. The goal is to develop international, interdisciplinary consensus for an accelerated neonatal antibiotic development programme.
The arrival of COVID-19 has brought profound and often tragic disruptions to every facet of life. In 2021, we have nonetheless witnessed more of the astounding achievements that can be made through global investment into the research and development of diagnostics, vaccines, and treatments.
After five years in operation, GARDP has formed numerous partnerships with industry, academia and research institutions in support of its clinical programmes to develop antibiotics for drug-resistant infections for children, newborns with sepsis (a bloodstream infection), sexually transmitted infections and serious bacterial infections. These collaborations span the drug development lifecycle and include screening chemical libraries for antibacterial activity, assessing the viability of potential antibiotic candidates, and the completion of three clinical trials.
Deutsch
GARDP is working to develop new and improved antibiotics to treat drug-resistant infections in children and babies. This report highlights the findings of a global neonatal sepsis observational study carried out by GARDP and partners at 19 hospitals in 11 countries from 2018 to 2020.
Doi: https://doi.org/10.1093/jac/dkac038 Authors: Christopher A. Darlow,Nicola Farrington,Adam Johnson,Laura McEntee,Jennifer Unsworth,Ana Jimenez-Valverde,Ruwanthi Kolamunnage-Dona,Renata M. A. Da Costa,Sally Ellis,François Franceschi, Mike Sharland,Michael Neely,Laura J. V. Piddock,Shampa Das,William … Flomoxef and fosfomycin in combination for the treatment of neonatal sepsis in the setting of highly prevalent antimicrobial resistance
DOI:https://doi.org/10.1016/S0140-6736(21)02724-0 About: This study provides the first comprehensive assessment of the global burden of AMR, as well as an evaluation of the availability of data. … Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis
Laura J. V. Piddock, Jean-Pierre Paccaud, Seamus O’Brien, Michelle Childs, Rohit Malpani, and Manica Balasegaram https://doi.org/10.1093/cid/ciab887 Antibiotics underpin modern medicine and are critical for pandemic … A Nonprofit Drug Development Model Is Part of the Antimicrobial Resistance (AMR) Solution
Nusrat Shafiq, Avaneesh Kumar Pandey, Samir Malhotra, Alison Holmes, Marc Mendelson, Rohit Malpani, Manica Balasegaram, Esmita Charani https://dx.doi.org/10.1136/bmjgh-2021-006961 Abstract: The lack of access to safe … Shortage of essential antimicrobials: a major challenge to global health security